The traditional DNMT inhibitors, especially 5-azacitidine and decitabine, have shown great clinical efficacy in hematologic malignancies, but lacked efficacy when used alongside immunotherapy in BLCA. This evidence concerns the gene DNMT1 and bladder transitional cell carcinoma.